JP7022079B2 - ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス - Google Patents

ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス Download PDF

Info

Publication number
JP7022079B2
JP7022079B2 JP2018562079A JP2018562079A JP7022079B2 JP 7022079 B2 JP7022079 B2 JP 7022079B2 JP 2018562079 A JP2018562079 A JP 2018562079A JP 2018562079 A JP2018562079 A JP 2018562079A JP 7022079 B2 JP7022079 B2 JP 7022079B2
Authority
JP
Japan
Prior art keywords
formula
compound
group
appearance
independent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018562079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518748A (ja
Inventor
バオ カイ，
ミッチェル マルティーニ，
ケイティ トーマス，
ロス シマブク，
Original Assignee
サレプタ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サレプタ セラピューティクス， インコーポレイテッド filed Critical サレプタ セラピューティクス， インコーポレイテッド
Publication of JP2019518748A publication Critical patent/JP2019518748A/ja
Application granted granted Critical
Publication of JP7022079B2 publication Critical patent/JP7022079B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018562079A 2016-06-30 2017-06-30 ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス Active JP7022079B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662357134P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US62/357,134 2016-06-30
US62/357,153 2016-06-30
US201762508256P 2017-05-18 2017-05-18
US62/508,256 2017-05-18
PCT/US2017/040311 WO2017205879A2 (fr) 2016-05-24 2017-06-30 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Publications (2)

Publication Number Publication Date
JP2019518748A JP2019518748A (ja) 2019-07-04
JP7022079B2 true JP7022079B2 (ja) 2022-02-17

Family

ID=64425889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562079A Active JP7022079B2 (ja) 2016-06-30 2017-06-30 ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス

Country Status (10)

Country Link
EP (1) EP3463389A4 (fr)
JP (1) JP7022079B2 (fr)
KR (1) KR102523522B1 (fr)
CN (1) CN109152792B (fr)
AU (1) AU2017270598B2 (fr)
CA (1) CA3024153A1 (fr)
CO (1) CO2018013831A2 (fr)
MX (1) MX2018014160A (fr)
SG (1) SG11201809502YA (fr)
WO (1) WO2017205879A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
MA45183A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
EP4230196A1 (fr) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Composés à utiliser dans le traitement des dystrophinopathies
KR20240105985A (ko) 2022-12-29 2024-07-08 최해용 스마트폰 용 프로젝터

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131624A1 (en) 2007-11-15 2009-05-21 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
JP2014159432A (ja) 2007-11-15 2014-09-04 Sarepta Therapeutics Inc モルホリノオリゴマーの合成方法
JP2016517279A (ja) 2013-03-14 2016-06-16 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
JP2016521119A (ja) 2013-03-14 2016-07-21 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
JP2019517605A (ja) 2016-06-30 2019-06-24 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
JP2019518832A (ja) 2016-05-24 2019-07-04 サレプタ セラピューティクス， インコーポレイテッド オリゴマー調製のためのプロセス
JP2019523754A (ja) 2016-05-24 2019-08-29 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
JP2019525742A (ja) 2016-06-30 2019-09-12 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0433345B1 (fr) 1988-09-01 1994-04-20 Forskningscenter Riso Procede de synthese de peptides et support solide de realisation dudit procede
AU694157B2 (en) * 1993-12-29 1998-07-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US9050373B2 (en) * 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
KR20200133284A (ko) * 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
WO2012150960A1 (fr) * 2011-05-05 2012-11-08 Avi Biopharma, Inc. Conjugués peptides/oligonucléotides
ES2727481T3 (es) * 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
WO2014189142A1 (fr) * 2013-05-24 2014-11-27 味の素株式会社 Procédé de fabrication de morpholino-oligonucléotide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131624A1 (en) 2007-11-15 2009-05-21 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
JP2014159432A (ja) 2007-11-15 2014-09-04 Sarepta Therapeutics Inc モルホリノオリゴマーの合成方法
JP2016517279A (ja) 2013-03-14 2016-06-16 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
JP2016521119A (ja) 2013-03-14 2016-07-21 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
JP2019518832A (ja) 2016-05-24 2019-07-04 サレプタ セラピューティクス， インコーポレイテッド オリゴマー調製のためのプロセス
JP2019523754A (ja) 2016-05-24 2019-08-29 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
JP2019517605A (ja) 2016-06-30 2019-06-24 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
JP2019525742A (ja) 2016-06-30 2019-09-12 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー

Also Published As

Publication number Publication date
EP3463389A2 (fr) 2019-04-10
KR102523522B1 (ko) 2023-04-20
CO2018013831A2 (es) 2018-12-28
CA3024153A1 (fr) 2017-11-30
CN109152792A (zh) 2019-01-04
WO2017205879A2 (fr) 2017-11-30
EP3463389A4 (fr) 2020-02-19
AU2017270598A1 (en) 2019-01-17
WO2017205879A3 (fr) 2018-01-18
KR20190020674A (ko) 2019-03-04
SG11201809502YA (en) 2018-12-28
AU2017270598B2 (en) 2022-12-01
MX2018014160A (es) 2019-04-01
CN109152792B (zh) 2021-09-14
JP2019518748A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
JP6987081B2 (ja) ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
TWI801843B (zh) 製備寡聚物之方法
JP7022079B2 (ja) ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
AU2017270975A1 (en) Processes for preparing phosphorodiamidate morpholino oligomers
JP7022078B2 (ja) ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
BR112018074330B1 (pt) Processo para preparar um composto oligomérico e compostos oligômeros morfolino fosforodiamidato
HK40016300A (en) Processes for preparing phosphorodiamidate morpholino oligomers
BR112018074340B1 (pt) Compostos oligômeros morfolino fosforodiamidato e processos para preparar os mesmos
BR122024017733A2 (pt) Compostos oligômeros morfolino fosforodiamidato e processos para preparar os mesmos
HK40005805A (en) Processes for preparing oligomers
HK40007452A (en) Processes for preparing phosphorodiamidate morpholino oligomers
HK40007452B (en) Processes for preparing phosphorodiamidate morpholino oligomers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220204

R150 Certificate of patent or registration of utility model

Ref document number: 7022079

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250